Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution.
about
Toxicity management of immunotherapy for patients with metastatic melanomaToxicities of Immunotherapy for the PractitionerClinical Update in Aspects of the Management of Autoimmune Thyroid DiseasesManagement of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab.Anticytotoxic T-lymphocyte antigen-4 induced autoimmune hypophysitis: a case report and literature review.Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study.Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma.Parathyroid Hormone-Related Peptide-Linked Hypercalcemia in a Melanoma Patient Treated With Ipilimumab: Hormone Source and Clinical and Metabolic CorrelatesPituitary Medicine From Discovery to Patient-Focused Outcomes.Immunotherapy for non-small cell lung cancer: current concepts and clinical trials.Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid CancerImmune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors.Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab.Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor TherapyAcute Hyperglycemia Associated with Anti-Cancer Medication.Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series.Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights.Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.Interleukin-2, Ipilimumab, and Anti-PD-1: Clinical Management and the Evolving Role of Immunotherapy for the Treatment of Patients With Metastatic Melanoma.Tremelimumab-Induced Graves Hyperthyroidism.Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.Atezolizumab for the treatment of non-small cell lung cancer.The Effect of Targeted Therapy for Genitourinary Malignancies on Sexual Function and Fertility.The Checkpoint Immunotherapy Revolution: What Started as a Trickle Has Become a Flood, Despite Some Daunting Adverse Effects; New Drugs, Indications, and Combinations Continue to EmergeIs autoimmunity the Achilles' heel of cancer immunotherapy?Treatment of Ipilimumab Induced Graves' Disease in a Patient with Metastatic Melanoma.Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions.Evolving molecularly targeted therapies for advanced-stage thyroid cancers.Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review.Checkpoint inhibition and melanoma: Considerations in treating the older adult.Immune-Related Adverse Events From Immune Checkpoint Inhibitors.Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab.Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.The confused oncologic patient: a rational clinical approach.The safety of anti PD-1 therapeutics for the treatment of melanoma.
P2860
Q26738662-23CF193E-1FF1-40C6-8C5D-F7849FE3D716Q27008140-BC89A2A4-FCFD-4E83-AD03-949C2EB588D4Q28075859-FBD00270-EC75-439A-B965-DD00D740B8E0Q31034415-29D5B7EB-D5B2-419C-88DB-D03310BEE301Q34664457-968B4E45-4448-4D7C-AC43-93E9DC50F7EDQ35074088-E434D5E8-89DB-4756-B34B-7F2583812260Q35102181-D1E00711-C0E9-4DC3-8FA7-31CC146966D7Q36132702-4B63A73E-2898-44FD-8424-911FA94D3E87Q36173638-FCFA62FF-DFF4-4B76-B989-A3B312E4DC1CQ36330197-0721C29E-5EA8-4922-B607-C9E21A585101Q36716025-D2BB042C-25CE-4BF2-A56C-B10564AD7A35Q36852170-FB37E443-D38F-4FD8-AA93-06E20D2C7790Q37057942-FB4823B6-DA7B-4641-AE80-5C5EF01BD7DEQ37091138-70C1777A-E26E-4B04-AD7C-F99E0978034DQ37131014-7B76DB47-1C9E-4D20-A859-6D0DF8C62F7BQ37265479-E0209DA7-9636-44F9-AA5A-0E6A620011F8Q37393253-6D767458-5372-4F40-83CF-78E691A61A05Q37629874-ABE75973-DD34-40F5-B1E7-EFBA5366DAA7Q37723241-B15498C8-C4C9-4701-955B-DBA6C9E5AB7AQ38502692-EB874F1B-6E4E-413E-BB59-093CEE9FCD0EQ38549542-ECEF87C8-9B8B-4B97-B61E-1DF696111F24Q38586991-27B2842A-2242-4800-ACC2-9160C2C57B08Q38595251-F41E6977-3472-4040-B965-1D93713ADF3EQ38635780-EB43DC1C-4593-4FBD-9EE7-43D3C432835FQ38673109-151A00F2-3916-47D3-95DE-02A4DFBA804FQ38675969-4C4EB97F-B397-4C96-ACB9-A52A146C8A3CQ38677185-2D3F71A6-0116-4E5D-A157-6D513E9B0D33Q38677347-8AE02498-2427-431E-90E6-9183277F7D10Q38687375-04147217-5283-4662-AA50-9D2484662990Q38735236-4BC7E3EC-EBFA-488E-9B63-274C22AE5AF0Q38735433-643BA33B-0E9E-4668-829A-344CF7993F84Q38754489-A716DDE6-B140-4CF0-AB50-B61FE5E3FB3BQ38783026-0A4A4A69-942C-4742-B019-ECA5350EFA77Q38785125-891FCF0E-FE15-4DE9-8E3F-0A251039DBC1Q38832640-A26AAA72-EA4D-4F82-8978-383C6DA46018Q38882247-411E1CB5-6DB9-49D9-A1BA-6C77ACAE0796Q38884560-3B9038BA-5BAC-4699-9915-F5294F5FDB6AQ38899873-2EFD791A-310A-4312-A506-6AA973528EE7Q38965811-68FF8068-1B84-44EF-8CAA-56B2F1FEEFBFQ38979801-CF701D27-0DC3-45D4-8BD0-9823558371CD
P2860
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Endocrine-related adverse even ...... iew from a single institution.
@ast
Endocrine-related adverse even ...... iew from a single institution.
@en
type
label
Endocrine-related adverse even ...... iew from a single institution.
@ast
Endocrine-related adverse even ...... iew from a single institution.
@en
prefLabel
Endocrine-related adverse even ...... iew from a single institution.
@ast
Endocrine-related adverse even ...... iew from a single institution.
@en
P2093
P2860
P356
P1476
Endocrine-related adverse even ...... iew from a single institution.
@en
P2093
James A Fagin
Jedd Wolchok
Mabel Ryder
Margaret Callahan
Michael A Postow
P2860
P304
P356
10.1530/ERC-13-0499
P577
2014-03-07T00:00:00Z